Is GW Pharmaceuticals Finally Getting Some Competition?
GW Pharmaceuticals (NASDAQ: GWPH) boasts the first plant-based cannabinoid pharmaceutical agent on the market with its treatment, Epidiolex. The Food and Drug Administration approved Epidiolex in June 2018 as a treatment for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS) in patients aged two or older. The European Medicines Agency followed suit, granting approval last September -- it sells in the EU under the name Epidyolex. GW has raked in more than $301.1 million since it began selling the drug on Nov. 1, 2018.
However, Fintepla, a competitive drug from Zogenix (NASDAQ: ZGNX), lurks on the horizon.
Image Source: Getty Images.
Source Fool.com
